BCAX (Bicara Therapeutics) Effective Interest Rate on Debt %: 0.00% (As of Mar. 2026)


BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $29.40
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics Effective Interest Rate on Debt %?

Bicara Therapeutics BCAX +0.10% 12 Effective Interest Rate on Debt % is 0.00% as of Mar. 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Bicara Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Mar. 2026 was $0.00 Mil. Bicara Therapeutics's average total debt for the quarter that ended in Mar. 2026 was $1.58 Mil. Therefore, Bicara Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 was 0.00%.

Bicara Therapeutics  (NAS:BCAX) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Bicara Therapeutics Effective Interest Rate on Debt % Related Terms

Bicara Therapeutics Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Effective Interest Rate on Debt % Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Effective Interest Rate on Debt %
0.00 0.00 0.00 0.00

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BCAX vs ZYME, SRPT, INVA: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, Bicara Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's Effective Interest Rate on Debt % falls into.


BCAX
12GF Score
Bicara Therapeutics Inc BCAX
Effective Interest Rate on Debt % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics Effective Interest Rate on Debt % Calculation

Bicara Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2024 )+Total Debt  (A: Dec. 2025 ))/ count )
=-1  *  0/( (0.738+1.71)/ 2 )
=-1  *  0/1.224
=0.00 %

where

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.131 + 0.607
=0.738

Total Debt  (A: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.593 + 1.117
=1.71

Bicara Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2025 )+Total Debt  (Q: Mar. 2026 ))/ count )
=-1  *  0/( (1.71+1.441)/ 2 )
=-1  *  0/1.5755
=0.00 %

where

Total Debt  (Q: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.593 + 1.117
=1.71

Total Debt  (Q: Mar. 2026 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.301 + 1.14
=1.441

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 0.00% mean?
Bicara Therapeutics (BCAX) has a Effective Interest Rate on Debt % of 0.00% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Bicara Therapeutics and its competitors.
Is Bicara Therapeutics' Effective Interest Rate on Debt % too high?
Bicara Therapeutics' current Effective Interest Rate on Debt % is 0.00%. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Effective Interest Rate on Debt % compare to ZYME and SRPT?
Bicara Therapeutics' Effective Interest Rate on Debt % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Bicara Therapeutics and its competitors. Bicara Therapeutics's current Effective Interest Rate on Debt % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Effective Interest Rate on Debt % of 0.00%. The current Effective Interest Rate on Debt % is 0.00%. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Effective Interest Rate on Debt % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.40
Price